Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999 ; 341 : 1565.
Ozaki S, Handa H, Saitoh T, et al. Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015 ; 5 : e349.
Ozaki S, Handa H, Koiso H, et al. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. J Cancer Res Clin Oncol 2022 ; 148 : 191.
San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013 ; 31 : 448.
Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019 ; 133 : 1953.